Development of Novel Fast GPU Monte Carlo and Active Photonics Simulation Software for Predicting PDT Efficacy

开发用于预测 PDT 功效的新型快速 GPU 蒙特卡罗和主动光子学仿真软件

• 批准号: 9138468
• 负责人: John R Cary
• 金额: $ 75.02万
• 依托单位: SIMPHOTEK, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-17 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9138468
• 关键词: Acceleration; Accounting; Aftercare; Air; Algorithms; Biological; Caring; Cells; Clinical; Code; Complex; Computer Architectures; Computer software; Computers; Computing Methodologies; Cytotoxic Chemotherapy; Development; Diffusion; Disease; Dose; Dose-Rate; Drug Interactions; Electromagnetic Energy; Equation; Exhibits; Foundations; Future; Goals; High Performance Computing; Hour; Kinetics; Legal patent; Light; Liquid substance; Malignant Neoplasms; Measurement; Measures; Modeling; Nature; Optics; PUVA Photochemotherapy; Patient-Focused Outcomes; Patients; Pennsylvania; Phase; Photobleaching; Photons; Physicians; Positioning Attribute; Process; Property; Radiation therapy; Reaction; Reporting; Research; Research Infrastructure; Research Personnel; Residual Tumors; Series; Singlet Oxygen; Small Business Innovation Research Grant; Software Tools; Source; Speed; Surface; System; Techniques; Tissues; Toxic effect; Treatment Efficacy; Treatment-Related Cancer; Universities; Writing; absorption; base; cancer therapy; cell killing; clinically relevant; cost; cytotoxic; dosimetry; effective therapy; graphical user interface; high end computer; improved; individualized medicine; innovation; light scattering; medical schools; meetings; multidisciplinary; neglect; novel; photonics; prototype; public health relevance; research clinical testing; simulation; simulation software; software development; therapy development; therapy outcome; tool; treatment planning; tumor; user friendly software

 DESCRIPTION (provided by applicant): Photodynamic therapy (PDT) provides for standalone or intraoperative cancer treatment. PDT provides a means to treat superficial and/or residual disease, while minimizing damage to underlying tissues, and does not exhibit cumulative cell toxicities, distinguishing it from radiation therapy. As compared to radiotherapy, treatment planning in PDT is often approached in a one-size-fits-all fashion. However, patient- and tumor-specific factors such as tissue optical properties and photosensitizer (PS) levels are critical to the delivery of effective light doses. The development of treatment dosimetry tools tha take into account these factors will fill an unmet clinical need and provide for individualized patient treatment. An effective PDT treatment dosimetry system stands to improve therapeutic outcomes, reduce the need for repeat PDT or additional cell-killing therapy, and could therefore reduce overall costs in the per patient delivery of cancer-related therapy and care. The major objective of this SBIR Phase II proposal is to develop and verify prototype software and hardware tools that combine simulations of PS photophysics with light propagation using fast Monte-Carlo (MC) techniques. The research of this Phase II SBIR will result in unique prototype dosimetry tools that will be further developed and commercialized in Phase III for use by PDT physicians and researchers to improve patient outcomes. This Phase II SBIR has three major aims. Aim 1 is to develop prototype software for PDT dosimetry combining light transport using fast Monte-Carlo (MC) techniques and patient PS variability. The software should be fast enough for future clinical use in Phase III of this project. At the foundation of this system will e Simphotek's novel Active Photonics Building Blocks (APBB) algorithm with its simple graphical user interface for active photophysics. The APBB breaks the computing problem for photophysics into a series of computational building blocks that the software automatically combines to generate the full numerical simulation. To include light scattering in the analysis, Simphotek has partnered with Tech-X Corporation (Tech-X; subaward), a leader in the field of high-performance computing. Tech-X has developed MC-based scattering infrastructure and has adapted the code in Phase I to model light diffusion and absorption processes in biological tissue. The Aim 2 objective is for Tech-X and Simphotek to develop a prototype PDT dosimetry tool combining both the software developed in Aim 1 and specialized hardware for high-speed simulations. Aim 3 is to verify the software/hardware simulations by comparing the simulation results to phantom measurements done at the University of Pennsylvania School of Medicine (Penn; subaward) by experts in PDT.

 描述（由申请人提供）：光动力疗法（PDT）可用于独立或术中癌症治疗。PDT提供了一种治疗浅表和/或残留疾病的方法，同时最大限度地减少对下层组织的损伤，并且不表现出累积的细胞毒性，将其与放射治疗区分开来。与放射疗法相比，PDT中的治疗计划通常以一种一刀切的方式进行。然而，患者和肿瘤特异性因素，如组织光学特性和光敏剂（PS）水平是关键的有效光剂量的输送。考虑到这些因素的治疗剂量测定工具的开发将填补未满足的临床需求，并提供个性化的患者治疗。有效的PDT治疗剂量测定系统能够改善治疗结果，减少对重复PDT或额外细胞杀伤治疗的需要，并且因此可以降低癌症相关治疗和护理的每位患者递送的总体成本。该SBIR第二阶段提案的主要目标是开发和验证原型软件和硬件工具，这些工具使用快速蒙特-卡罗（MC）技术将PS物理学与光传播的联合收割机模拟相结合。这项第二阶段SBIR的研究将产生独特的原型剂量测定工具，这些工具将在第三阶段进一步开发和商业化，供PDT医生和研究人员使用，以改善患者的治疗效果。第二阶段SBIR有三个主要目标。目的1是开发PDT剂量测定的原型软件，结合使用快速蒙特-卡罗（MC）技术和患者PS变异性的光传输。该软件应足够快，可用于本项目III期的未来临床使用。在这个系统的基础上，将使用Simphotek的新颖的有源光子学构建块（APBB）算法及其简单的图形用户界面进行有源光子物理学。APBB将物理学的计算问题分解为一系列计算构建块，软件自动组合这些计算构建块以生成完整的数值模拟。为了在分析中包括光散射，Simphotek与高性能计算领域的领导者Tech-X Corporation（Tech-X; subaward）合作。Tech-X已经开发了基于MC的散射基础设施，并在第一阶段采用了代码来模拟生物组织中的光扩散和吸收过程。Aim 2的目标是让Tech-X和Simphotek开发一种原型PDT剂量测定工具，将Aim 1中开发的软件和用于高速模拟的专用硬件结合起来。目的3是通过比较模拟结果与PDT专家在宾夕法尼亚大学医学院（Penn; subaward）进行的体模测量来验证软件/硬件模拟。